View Older Stories View More Recent Stories

May 7, 2025 02:30AM Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
May 7, 2025 02:15AM Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
Apr 29, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 29, 2025 08:31AM Gilead Sciences (GILD) to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
Apr 29, 2025 08:30AM Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
Apr 21, 2025 08:31AM Gilead Sciences (GILD); Trodelvy Plus Keytruda Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients With nTNBC
Apr 21, 2025 08:30AM Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Ne
Apr 10, 2025 04:05PM Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
Mar 12, 2025 08:31AM Gilead Sciences (GILD) Presents New HIV Treatment and Cure Research Data
Mar 12, 2025 08:30AM Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Mar 11, 2025 01:38PM Gilead Sciences (GILD) Presents First Clinical Data for Investigational Once-Yearly Lenacapavir for HIV Prevention
Mar 11, 2025 01:37PM First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Feb 24, 2025 08:30AM European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
Feb 20, 2025 04:30PM Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Feb 19, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Feb 18, 2025 08:30AM Gilead Sciences (GILD): U.S. FDA Accepts New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Feb 18, 2025 08:30AM U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Feb 11, 2025 04:05PM Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
Jan 28, 2025 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Jan 22, 2025 08:30AM Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
Jan 11, 2025 11:00AM Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Dec 20, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 17, 2024 08:33AM Gilead Sciences (GILD) Granted FDA Breakthrough Therapy Designation to Trodelvy
Dec 17, 2024 08:30AM U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Dec 17, 2024 07:02AM Gilead Sciences (GILD) and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Dec 17, 2024 07:00AM Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Dec 12, 2024 05:30PM Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Dec 3, 2024 07:00AM Gilead Sciences (GILD) and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Dec 3, 2024 07:00AM Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Nov 27, 2024 05:01PM Gilead Sciences (GILD) Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Nov 27, 2024 05:00PM Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Nov 15, 2024 11:01AM Gilead Sciences (GILD) Reports Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Nov 15, 2024 11:00AM Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Nov 13, 2024 06:46AM Gilead Sciences (GILD) Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention
Nov 13, 2024 06:45AM Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Nov 12, 2024 05:30AM Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
Nov 8, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Engagements
Nov 7, 2024 08:30AM Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Oct 22, 2024 09:00AM Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
Oct 21, 2024 05:59AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 21, 2024 05:58AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 19, 2024 05:09PM Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Wee
Oct 9, 2024 04:05PM Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Oct 9, 2024 08:35AM Gilead Sciences (GILD) to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek
Oct 9, 2024 08:30AM Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Oct 7, 2024 11:00AM Gilead Sciences (GILD) Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Oct 7, 2024 11:00AM Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Oct 2, 2024 08:32AM Gilead Sciences (GILD) Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countri
Oct 2, 2024 08:30AM Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
Sep 12, 2024 08:30AM Gilead's (GILD) Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada
View More Recent Stories View Older Stories